Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

被引：0
|
作者：
Agata Ptaszynska
Kristina M. Johnsson
Shamik J. Parikh
Tjerk W. A. de Bruin
Anne Marie Apanovitch
James F. List
机构：
[1] Bristol-Myers Squibb,
[2] Global Clinical Research,undefined
[3] Research and Development,undefined
[4] AstraZeneca,undefined
[5] Research and Development,undefined
[6] AstraZeneca,undefined
[7] Global Medicines Development,undefined
[8] Bristol-Myers Squibb,undefined
[9] Global Biometric Sciences,undefined
[10] Research and Development,undefined
来源：
Drug Safety | 2014年 / 37卷
关键词：
Placebo Group; Metformin; Uric Acid Level; Glipizide; Urinary Stone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：815 / 829
页数：14
相关论文
共 50 条
  • [1] Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
    Ptaszynska, Agata
    Johnsson, Kristina M.
    Parikh, Shamik J.
    de Bruin, Tjerk W. A.
    Apanovitch, Anne Marie
    List, James F.
    DRUG SAFETY, 2014, 37 (10) : 815 - 829
  • [2] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Engel, Samuel S.
    Round, Elizabeth
    Golm, Gregory T.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES THERAPY, 2013, 4 (01) : 119 - 145
  • [3] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Samuel S. Engel
    Elizabeth Round
    Gregory T. Golm
    Keith D. Kaufman
    Barry J. Goldstein
    Diabetes Therapy, 2013, 4 : 119 - 145
  • [4] Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies
    Elizabeth M. Round
    Samuel S. Engel
    Gregory T. Golm
    Michael J. Davies
    Keith D. Kaufman
    Barry J. Goldstein
    Drugs & Aging, 2014, 31 : 203 - 214
  • [5] Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Samuel S. Engel
    Elizabeth Round
    Gregory T. Golm
    Keith D. Kaufman
    Barry J. Goldstein
    Diabetes Therapy, 2013, 4 : 487 - 487
  • [6] Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies
    Round, Elizabeth M.
    Engel, Samuel S.
    Golm, Gregory T.
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DRUGS & AGING, 2014, 31 (03) : 203 - 214
  • [7] Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus
    Johnsson, K.
    Ptaszynska, A.
    Apanovitch, A.
    Sugg, J. E.
    Parikh, S. J.
    List, J. F.
    DIABETOLOGIA, 2012, 55 : S304 - S304
  • [8] SAFETY OF DAPAGLIFLOZIN IN CLINICAL TRIALS FOR TYPE 2 DIABETES MELLITUS
    Ptaszynska, Agata
    Johnsson, Kristina
    Apanovitch, Anne Marie
    Sugg, Jennifer
    Parikh, Shamik
    List, James
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 50 - 50
  • [9] Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
    Jabbour, Serge
    Seufert, Jochen
    Scheen, Andre
    Bailey, Clifford J.
    Karup, Cathrina
    Langkilde, Anna M.
    DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 620 - 628
  • [10] Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
    Paola Fioretto
    Traci A. Mansfield
    Agata Ptaszynska
    Yshai Yavin
    Eva Johnsson
    Shamik Parikh
    Drugs & Aging, 2016, 33 : 511 - 522
12345